tbuckley/cabot-search huggingface dataset:
Anterior Sacral Meningocele
Authors: Burhan Say
Journal: JAMA (1977)

To the Editor.—  We have read with great interest the article by Drs Anderson and Burke (237:39, 1977). We believe their article deserves further comments regarding the genetic aspects of sacral defects with associated malformations. In addition to those familial cases cited by the authors, Cohn and Bay-Nielsen 1 reported a family with six cases of the absence of the sacrum and coccyx, four of whom also had a presacral mass. The diagnosis of anterior meningocele was established by myelography in their patients whose symptoms mainly consisted of constipation and urinary incontinence (the same symptoms as those in the patients presented by Anderson and Burke). Cohn and Bay-Nielsen concluded that this condition was most likely the result of an X-linked dominant gene. In 1975, we reported another such family, 2 which supported their conclusion. Furthermore, we suggested that the gene may act as a lethal in hemizygous males, since two
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Authors: Maryam Sarraf Yazdy, Anthony R. Mato, Lindsey E. Roeker, Umair Jarral, Chaitra S. Ujjani, Mazyar Shadman, Alan Skarbnik, Kate J Whitaker, Isaac Deonarine, Charlene C. Kabel, Sarah E. Stump, Julie Goodfriend, John M. Pagel, Neil Bailey, Krish Patel, Ryan Jacobs, Tatyana A. Feldman, Lori A. Leslie, Andre Goy, Catherine C. Coombs, Benyam Muluneh, Sirin Khajavian, Nicole Lamanna, Hanna Weissbrot, Jessica Weiss, Bruce D. Cheson
Journal: Blood (2019)
EXTH-50. THIOREDOXIN REDUCTASE1 AND MGMT SYNTHETIC LETHALITY ENHANCES CYTOTOXICITY OF PRIMA-1MET(APR-246) AND AURANOFIN IN GLIOBLASTOMA
Authors: Rehka Raveendrakumar, Bassam Abdulkarim, Monisha Bagchi, Paul Daniel, Aymane Deri, Bertrand Jean-Claude, Siham Sabri
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma multiforme (GBM), the most common and advanced primary brain malignancy in adults remains an incurable disease, despite aggressive treatment with surgery, radiation therapy and chemoradiation using the alkylating agent, Temozolomide (TMZ). PRIMA-1MET (APR-246), a small molecule designed to restore mutant (mut)p53 function has been shown to affect cellular redox status through targeting thioredoxin reductase 1 (TrxR1) in wild-type (wt)p53 cancer cells. We have recently shown that PRIMA-1MET exerts cytotoxic effects status preferentially in GBM cell lines expressing low levels of the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), known for its role in resistance to TMZ. We hypothesized that PRIMA-1MET mediates its growth inhibitory effects by modulating the redox balance and investigated the potential relationship between MGMT, redox balance and TrxR1. We show that PRIMA-1MET decreased TrxR1 expression levels preferentially in MGMT-low expressing isogenic GBM cell lines. Using pharmacological agents that modulate reactive oxygen species (ROS) levels i.e., ROS scavenger, N-acetylcysteine and ROS inducer, L-Buthionine-Sulfoximine, we show that PRIMA-1MET exerts its growth-inhibitory effects through increased ROS. Strikingly, we identified a novel positive relationship between MGMT and TrxR1, wherein high MGMT expression is associated with high expression of TrxR1 and low levels of ROS. Treatment with the MGMT inhibitor, O6-Benzylguanine, or the TrxR1-targeting FDA-approved drug Auranofin validated our findings. Interestingly, the latter exerted significantly more pronounced cytotoxic effects compared to PRIMA-1MET in GBM cell lines. Additional studies are warranted to assess PRIMA-1MET in combination with TrxR1-targeting therapies and propose repurposing of Auranofin as a novel strategy to improve the dismal outcome of patients with GBM.
Tenosynovitis of the Wrist
Authors: M. Ellis
Journal: BMJ (1951)

GLANDULAR FEVER WITH ENCEPHALITISBRiIH 777-. ~~~~MEDICAL JouRNAL only, but she relapsed a week later.She again responded promptly when again given the drug, and this was con- tinued for one week without further relapse.The other case, of seven months' duration, responded promptly, and had not relapsed three months after discontinuance of the drug.Although most cases of glandular fever are reiatively benign and require only symptomatic treat- ment, some severe ones often leave behind a state of depression and debility which may predispose to more serious illness (indeed, I have seen two cases which within a few weeks returned with a tuberculous pleural effusion), and in these cases if chloramphenicol is likely to shorten the illness it may be worth a trial. SummaryA case of glandular fever with encephalitis is reported.The Paul-Bunnell test was positive, and the blood showed typical cell changes.In spite of the clinical encephalitis, the cerebrospinal fluid was normal on the five occasions it was tested.Chloramphenicol was used in treatknent: its use in glandular fever is discussed.I wish to thank Dr. C.
Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Authors: Vibe Skov, Caroline Riley, Mads Thomassen, Lasse Kjær, Thomas Stauffer Larsen, Torben A Kruse, Hans Hasselbalch
Journal: Blood (2019)
Measuring Handrim Wheelchair Propulsion in the Lab: A Critical Analysis of Stationary Ergometers
Authors: Rick de Klerk, Riemer Jakobs K. Vegter, Vicky L. Goosey-Tolfrey, Barry S. Mason, John P. Lenton, Dirkjan H. E. J. Veeger, Lucas H. V. van der Woude
Journal: IEEE Reviews in Biomedical Engineering (2019)

There are many ways to simulate handrim wheelchair propulsion in the laboratory. Ideally, these would be able to, at least mechanically, simulate field conditions. This narrative review provides an overview of the lab-based equipment used in published research and critically assesses their ability to simulate and measure wheelchair propulsion performance. A close connection to the field can only be achieved if the instrument can adequately simulate frictional losses and inertia of real-life handrim wheelchair propulsion, while maintaining the ergonomic properties of the wheelchair-user interface. Lab-based testing is either performed on a treadmill or a wheelchair ergometer (WCE). For this study WCEs were divided into three categories: roller, flywheel, and integrated ergometers. In general, treadmills are mechanically realistic, but cannot simulate air drag and acceleration tasks cannot be performed; roller ergometers allow the use of the personal wheelchair, but calibration can be troublesome; flywheel ergometers can be built with commercially-available parts, but inertia is fixed and the personal wheelchair cannot be used; integrated ergometers do not employ the personal wheelchair, but are suited for the implementation of different simulation models and detailed measurements. Lab-based equipment is heterogeneous and there appears to be little consensus on how to simulate field conditions.
Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab
Authors: Patricia Eiko Yamakawa, Ana Rita Da Fonseca, Iara Baldim Rabelo Gomes, Vinicius Campos de Molla, Andre Domingues Pereira, Roberta Shcolnik Szor, Martha Mariana Arruda, Maria Stella Figueiredo, Celso Arrais-Rodrigues
Journal: Blood (2019)
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
Authors: Veronika Bachanova, Constantine S. Tam, Peter Borchmann, Ulrich Jaeger, Joseph P. McGuirk, Harald Holte, Edmund K. Waller, Samantha Jaglowski, Michael R. Bishop, Charalambos Andreadis, Stephen Ronan Foley, Jason R. Westin, Isabelle Fleury, P Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J Schuster, Richard T. Maziarz, Koen Van Besien, Koji Izutsu, Marie Jose Kersten, John M. Magenau, Nina D. Wagner-Johnston, Koji Kato, Paolo Corradini, Jufen Chu, Irina Gershgorin, Therese Choquette, Lida Bubuteishvili Pacaud, Margit Jeschke
Journal: Blood (2019)
PATH-08. CHALLENGES IN OPTIMIZATION OF MGMT PROMOTER METHYLATION ASSAYS FOR DEVELOPMENT OF COMPANION DIAGNOSIS IN GLIOBLASTOMA
Authors: Motoo Nagane, Kuniaki Saito, Keiichi Kobayashi, Saki Shimizu, Nobuyoshi Sasaki, Yuki Yamagishi, Yoshiaki Shiokawa
Journal: Neuro-Oncology (2019)

Abstract BACKGROUNDS Despite recent limelight of precision medicine in oncology, effective targeted drugs and diagnostics for molecular markers have not been developed or approved for glioblastoma (GBM) yet. Notably, there remain multiple issues in MGMT testing, including determination of optimal assays and cutoff for methylation status, and its value as “companion diagnostics.” We compared two of MGMT assays, qualitative standard MSP and pyrosequencing, in light of compatibility, predictability, and cutoff points. METHODS Sixty-five newly diagnosed GBMs with two MGMT assays performed since 2006. Survival was analyzed for 48 GBMs with wildtype IDH and initial temozolomide use. Extracted DNA was subjected to bisulfite treatment, thereby MGMT status was determined. RESULTS Among 65 GBMs, MGMT was methylated (M) in 34, and unmethylated (U) in 31, by MSP. Median methylation rate at CpG sites by Pyro was 15.9%, with average 23.0% for M and 9.5% for U (Mann-Whitney-U, P&lt; 0.001). MGMT status by MSP significantly correlated with that by Pyro with cutoff between 10 – 16% (Fisher, P&lt; 0.001). Patients with MGMT M by MSP showed significantly longer PFS and OS than with U (PFS 13.5 m vs. 5.6 m, P = 0.005; OS 37.7 m vs. 15.8 m, P = 0.001). In contrast, by Pyro (cutoff 14%), only PFS was significantly better in M (11.7 m vs 5.6 m, P = 0.014), but not OS (27.9 m vs. 15.8 m, P = 0.249). No substantial gain for PFS was noted in MGMT M GBMs beyond cutoff 12% by Pyro. Multivariate analysis revealed MGMT M and KPS 70 or higher as independent factors for better PFS and OS using MSP, but only for PFS with Pyro. CONCLUSIONS In this study, qualitative MSP exhibited rather better discrimination of prognosis than quantitative Pyro, although showing a high concordance for MGMT status, necessitating further confirmation among assays.
Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)
Authors: Juan-Manuel Sancho, Olga García, Pablo Mozas, Santiago Mercadal, Eva Donato, Ana Muntañola Prat, Javier Lopez Jimenez, Pascual Fernandez Abellan, Jose-Angel Hernandez, Maria J. Rodriguez-Salazar, Samuel Romero, Ana Marin Niebla, Angel Ramirez Payer, Raul Cordoba, Jose Luis Bello, Beatriz Cuevas, Itziar Oiartzabal, Alejandro Martín, Jose Javier Sanchez Blanco, Nicholas Kelleher, Ana Lafuente, Marc Sorigué, López Guillermo Armando
Journal: Blood (2019)
Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort
Authors: Zaid Abdel Rahman, Michael G. Heckman, Kevin C. Miller, Patricia Greipp, Matthew R Spiegel, Sharad Khurana, Hassan B. Alkhateeb, Mrinal M Patnaik, Lisa Z. Sproat, Liuyan Jiang, Vivek Roy, Mark Litzow, Mohamed A Kharfan-Dabaja, William J Hogan, James M. Foran
Journal: Blood (2019)
Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial
Authors: Mark J. Levis, Siddhartha Ganguly, Samer K. Khaled, Alwin Krämer, Giovanni Martinelli, Alexander E. Perl, Nigel H. Russell, Youngsook Choi, Arnaud Lesegretain, Jeanne Mendell, Derek E. Mires, Yufen Zhang, Jorge E. Cortes
Journal: Blood (2019)
One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)
Authors: Dietger Niederwieser, Helen Baldomero, Yoshiko Atsuta, Mahmoud Aljurf, Adriana Seber, Hildegard T. Greinix, Mickey Koh, Nina Worel, Sebastian Galeano, Gregorio Jaimovich, Juliana Martinez Rolon, Yoshihisa Kodera, Malek Benakli, Nosa Bazuaye, Cristobal Augusto Frutos Ortiz, Rolandas Gerbutavicius, Alaa M. Elhaddad, Nicolas Novitzky, Jeffrey Szer, Jakob R. Passweg, Nicolaus Kröger, Daniel J. Weisdorf, Marcelo C. Pasquini
Journal: Blood (2019)
Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma
Authors: Ankur K. Nagaraja, Osamu Kikuchi, Adam J. Bass
Journal: Cancer Discovery (2019)

Abstract Gastroesophageal adenocarcinomas (GEA) are devastating diseases with stark global presence. Over the past 10 years, there have been minimal improvements in treatment approach despite numerous clinical trials. Here, we review recent progress toward understanding the molecular features of these cancers and the diagnostic and therapeutic challenges posed by their intrinsic genomic instability and heterogeneity. We highlight the potential of genomic heterogeneity to influence clinical trial outcomes for targeted therapies and emphasize the need for comprehensive molecular profiling to guide treatment selection and adapt treatment to resistance and genomic evolution. Revising our clinical approach to GEA by leveraging genomic advances will be integral to the success of current and future treatments, especially as novel targets become therapeutically tractable. Significance: GEAs are deadly cancers with few treatment options. Characterization of the genomic landscape of these cancers has revealed considerable genetic diversity and spatial heterogeneity. Understanding these fundamental properties of GEA will be critical for overcoming barriers to the development of novel, more effective therapeutic strategies.
Dasatinib Inhibits FLT3/ITD and PTPN11mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases
Authors: Sigal Tavor, Tali Shalit, Noa Chapal Ilani, Yoni Moskovitz, Nir Livnat, Yoram Groner, Haim Bar, Alexander Plotnikov, Nathali Kaushansky, Liran I. Shlush
Journal: Blood (2019)
RARE-49. SEX-SPECIFIC SURVIVAL ANALYSIS IDENTIFIES DIFFERENTIAL CLUSTERS OF PROGNOSTIC RELEVANCE IN PATIENTS WITH PRIMARY CNS LYMPHOMA
Authors: Thomas Roetzer, Karl-Heinz Nenning, Julia Furtner, Lukas Seebrecht, Johanna Gesperger, Adelheid Woehrer
Journal: Neuro-Oncology (2019)

Abstract Sex-specific differences are increasingly recognized in various diseases but have not yet been investigated for patients with primary CNS lymphoma (PCNSL). We collected clinical information and MR-images from 130 patients with PCNSL (66 f/ 64 m). We segmented MR-images into contrast-enhanced tumor, necrosis and edema for volumetric analysis and additionally quantified anti-PCNSL immune response using anti-CD3 staining in 67 cases. Median overall survival was 10 months for females and 8 months for males (p=0.979). Sex-specific Cox-regression analyses implicated age, performance and immunodeficiency as significant prognostic markers in females, whereas only age remained as significant marker in males. We then performed cluster analyses for females (fC) and males (mC) with complete sets of clinical, imaging, and tissue phenotypes (n=55). In females, two main clusters emerged that were mainly driven by clinical performance with fC1 (n=14) featuring patients with better performance (most of whom received MTX) compared to fC2 (n=18; mOS 21 vs 3 months, p&lt; 0.01). fC2 resolved into two subclusters with better outcome for fC2a based on larger enhancing tumor volume and high immune response (mOS 12 vs. 1 months, p&lt; 0.01). In males, two major clusters emerged (16 vs 7 patients, mOS 5 vs 23 months, p=0.414).), which differed mainly according to treatment approach with higher prevalence of MTX-chemotherapy in mC1. Each cluster could be subdivided into 2 subclusters based on differences in clinical performance in mC1, or according to treatment strategy, i.e., combined chemo-radiotherapy vs radiotherapy-only or best supportive care (mOS 49 vs 2 months, p=0.12) in mC2. In summary, we find prognostically relevant sex-specific clusters in patients with PCNSL that implicate differential roles of tumor-related contrast enhancement and immune response in female versus treatment modality in male patients. Initial differences in cluster-defining factors need further validation in independent cohorts but might have implications for differential patient management.
CBMT-03. EVALUATION OF PET TRACERS TO DIFFERENTIATE IDH1 MUTANT GBM
Authors: Andrei Molotkov, Angeliki Mela, Peter D Canoll, Akiva Mintz
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE PET/CT offers the unique potential to noninvasively evaluate biomarker expression and aberrant metabolism. 18F-FDG has driven PET/CT to the forefront of cancer imaging, as altered glucose metabolism is a hallmark of oncogenesis. However, 18F-FDG is suboptimal for GBM due to high physiologic uptake in normal brain. The development of alternative tracers has reignited the field of PET/CT in GBM and offers hope for diagnosis and molecular staging in GBM. We hypothesize that fundamental differences in metabolism and oncogene expression present in IDH1 mutatant gliomas can be shown using PET imaging, as has been suggested in some correlative clinical studies. Our objective was therefore to establish a causal link between IDH1 mutation in GBM and uptake of targeted PET tracers in a unique proneural GBM transgenic model characterized by p53, IDH1 mutations and PDGF expression. METHODS We examined the uptake of 3 blood-brain-barrier (BBB) penetrant tracers that have been used in GBM: (a) 18F-FDG, a surrogate for increased glycolysis; (b) 18F-Fluciclovine, an amino acid derivative transported into cells through the energy-independent L-type amino acid transporter (LAT) system and is approved by the FDA for prostate cancer; and (c) 11C-ER176, a tracer that binds the TSPO receptor that is generally expressed on activated microglia as well as GBM. RESULTS We did not observe significant differences in 18F-FDG uptake between wt and IDH mutant GBM cells. However, we found that IDH mutant GBM cells demonstrated significantly increased 18F-Fluciclovine (47%) and 11C-ER176 (53%) versus IDH wt cells. CONCLUSION We have established a causal link between IDH mutation status and uptake of (a) 18F-Fluciclovine, a promising FDA approved PET tracer and (b) 11C-ER176, a second generation TSPO ligand. Thus, we are performing further studies in orthotopic syngeneic GBM models to determine if PET imaging can non-invasively demonstrate molecular characterization and therapeutic stratification in glioma.
RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia
Authors: Andoni Garitano-Trojaola, Ana Sancho, Ralph Goetz, Susanne Walz, Hardikkumar Jetani, Eva Teufel, Nadine Rodhes, Matteo DaVia, Larissa Haertle, Silvia Nerreter, Cornelia Vogt, Johannes Duell, Raoul Tibes, Sabrina Kraus, Andreas Rosenwald, Leo Rasche, Michael Hudecek, Markus Sauer, Hermann Einsele, Jürgen Groll, Martin Kortüm
Journal: Blood (2019)
Differences in Progression to Obstructive Lesions per High-Risk Plaque Features and Plaque Volumes With CCTA
Authors: Sang-Eun Lee, Ji Min Sung, Daniele Andreini, Mouaz H. Al-Mallah, Matthew J. Budoff, Filippo Cademartiri, Kavitha Chinnaiyan, Jung Hyun Choi, Eun Ju Chun, Edoardo Conte, Ilan Gottlieb, Martin Hadamitzky, Yong Jin Kim, Byoung Kwon Lee, Jonathon A. Leipsic, Erica Maffei, Hugo Marques, Pedro de Araújo Gonçalves, Gianluca Pontone, Gilbert L. Raff, Sanghoon Shin, Peter H. Stone, Habib Samady, Renu Virmani, Jagat Narula, Daniel S. Berman, Leslee J. Shaw, Jeroen J. Bax, Fay Y. Lin, James K. Min, Hyuk-Jae Chang
Journal: JACC. Cardiovascular imaging (2019)
Impact of youth sports specialisation on career and task-specific athletic performance: a systematic review following the American Medical Society for Sports Medicine (AMSSM) Collaborative Research Network’s 2019 Youth Early Sport Specialisation Summit
Authors: Stephanie A Kliethermes, Kyle Nagle, Jean Côté, Robert M Malina, Avery Faigenbaum, Andrew Watson, Brian Feeley, Stephen William Marshall, Cynthia R LaBella, Daniel C Herman, Adam Tenforde, Anthony I Beutler, Neeru Jayanthi
Journal: British Journal of Sports Medicine (2019)

The impact, positive or negative, of youth sport specialisation (YSS) on short-term and long-term performance is not fully understood; however, the desire to maximise performance goals is generally considered the primary reason children and adolescents specialise at a young age. We performed a systematic review of original research to establish the association of YSS and task-focused or career-focused performance outcomes.Systematic review.Databases searched include PubMed, EMBASE, Cochrane, CINAHL and SPORTDiscus.We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify peer-reviewed research articles published in English between 1 January 1990 and 31 December 2018 that reported original findings on the association of YSS and performance outcomes. Studies without an explicit measure of sport specialisation, for example, volume measures without measuring sport specialisation, were excluded.Twenty-two articles were included in the final review; 15 addressed career performance outcomes and 7 considered task performance outcomes. All identified studies were cross-sectional or retrospective in design. The proportion of elite athletes who specialised early ranged between 7% and 85%, depending on sport and definition of specialisation. Elite athletes often specialised between the ages of 14 and 15 compared with their non-elite or semi-elite peers who typically specialised prior to 13 years. In addition, neuromuscular control, anterior reach asymmetry and physical task outcomes did not differ by specialisation status.The volume and methodological rigour of published research in this field are limited. Our review suggests that YSS is not required to achieve success at elite levels. YSS also does not appear to improve task-related performance (eg, anterior reach, neuromuscular control) outcomes for specialised athletes when compared with non-specialised athletes during childhood and adolescence.
Neutrophilic asthma: welcome back!
Authors: Peter G. Gibson, Paul S. Foster
Journal: European Respiratory Journal (2019)

<b>Bullone and co-workers show that neutrophilic asthma is a subtype in which the IL-17 pathway seems to be operational. It can be recognised by quantitative immunostaining of bronchial biopsy specimens and may be amenable to specific targeted therapies.</b>http://bit.ly/2llj6Fr
A Miniaturized Microfluidic Dielectric Sensor for Point-of-Care Assessment of Blood Coagulation
Authors: Evi X. Stavrou, Michael A. Suster, Debnath Maji, Erdem Kucukal, Ujjal Didar Singh Sekhon, Alvin H. Schmaier, Anirban Sen Gupta, Umut A. Gurkan, Pedram Mohseni
Journal: Blood (2016)
Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients
Authors: Paola Neri, Ranjan Maity, Jean-Baptiste Alberge, Sarthak Sinha, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, Nizar Bahlis
Journal: Blood (2019)
Greatalys: Generating Real World Evidence across Italy in Sickle Cell Disease
Authors: Chiara Castiglioni, Claudia Condorelli, Paola Amore, Valentina Perrone, Davide Alessandrini, Chiara Veronesi, Luca Degli Esposti, Eleonora Premoli, Carina Fiocchi
Journal: Blood (2019)